Likewise, in 22 RCC patients (20 CRCC patients, 1 CRCC patient, and 1 transitional cell carcinoma), patient management as defined based on initial diagnostic CT findings was changed in 13 out of 20 patients following subsequent 68Ga-PSMA HEBD-CC PET/CT imaging performed at restaging: in 4/9 patients, new sites of metastatic disease were identified; in 5/9 patients, 68Ga-PSMA-HBED-CC PET/CT imaging refuted disease; and in another 4 patients, a synchronous primary prostate carcinoma was identified. The gene discussed is FOLH1; the disease is chromophobe renal cell carcinoma.